Literature DB >> 22438252

Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia.

Michaël Porcu1, Maria Kleppe, Valentina Gianfelici, Ellen Geerdens, Kim De Keersmaecker, Marco Tartaglia, Robin Foà, Jean Soulier, Barbara Cauwelier, Anne Uyttebroeck, Elizabeth Macintyre, Peter Vandenberghe, Vahid Asnafi, Jan Cools.   

Abstract

The protein tyrosine phosphatase CD45, encoded by the PTPRC gene, is well known as a regulator of B- and T-cell receptor signaling. In addition, CD45 negatively regulates JAK family kinases downstream of cytokine receptors. Here, we report the presence of CD45 inactivating mutations in T-cell acute lymphoblastic leukemia. Loss-of-function mutations of CD45 were detected in combination with activating mutations in IL-7R, JAK1, or LCK, and down-regulation of CD45 expression caused increased signaling downstream of these oncoproteins. Furthermore, we demonstrate that down-regulation of CD45 expression sensitizes T cells to cytokine stimulation, as observed by increased JAK/STAT signaling, whereas overexpression of CD45 decreases cytokine-induced signaling. Taken together, our data identify a tumor suppressor role for CD45 in T-cell acute lymphoblastic leukemia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22438252     DOI: 10.1182/blood-2011-09-379958

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.

Authors:  Sandrine Degryse; Simon Bornschein; Charles E de Bock; Emilie Leroy; Marlies Vanden Bempt; Sofie Demeyer; Kris Jacobs; Ellen Geerdens; Olga Gielen; Jean Soulier; Christine J Harrison; Stefan N Constantinescu; Jan Cools
Journal:  Blood       Date:  2017-11-29       Impact factor: 22.113

Review 2.  Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy.

Authors:  Thomas A Waldmann; Jing Chen
Journal:  Annu Rev Immunol       Date:  2017-02-09       Impact factor: 28.527

3.  Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia.

Authors:  Marc R Mansour; Casie Reed; Amy R Eisenberg; Jen-Chieh Tseng; Jean-Claude Twizere; Sarah Daakour; Akinori Yoda; Scott J Rodig; Noa Tal; Chen Shochat; Alla Berezovskaya; Daniel J DeAngelo; Stephen E Sallan; David M Weinstock; Shai Izraeli; Andrew L Kung; Alex Kentsis; A Thomas Look
Journal:  Br J Haematol       Date:  2014-09-26       Impact factor: 6.998

Review 4.  JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.

Authors:  Lorraine Springuel; Jean-Christophe Renauld; Laurent Knoops
Journal:  Haematologica       Date:  2015-10       Impact factor: 9.941

5.  Progenitor B-1 B-cell acute lymphoblastic leukemia is associated with collaborative mutations in 3 critical pathways.

Authors:  Sheryl M Gough; Liat Goldberg; Marbin Pineda; Robert L Walker; Yuelin J Zhu; Sven Bilke; Yang Jo Chung; Joseph Dufraine; Subhadip Kundu; Elad Jacoby; Terry J Fry; Susanna Fischer; Renate Panzer-Grümayer; Paul S Meltzer; Peter D Aplan
Journal:  Blood Adv       Date:  2017-09-08

6.  DNA methylation of membrane-bound tyrosine phosphatase genes in acute lymphoblastic leukaemia.

Authors:  W S Stevenson; O G Best; A Przybylla; Q Chen; N Singh; M Koleth; S Pierce; T Kennedy; W Tong; S-Q Kuang; G Garcia-Manero
Journal:  Leukemia       Date:  2013-09-18       Impact factor: 11.528

7.  Deregulation of protein phosphatase expression in acute myeloid leukemia.

Authors:  Nuzhat N Kabir; Lars Rönnstrand; Julhash U Kazi
Journal:  Med Oncol       Date:  2013-02-26       Impact factor: 3.064

8.  TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia.

Authors:  Takaomi Sanda; Jeffrey W Tyner; Alejandro Gutierrez; Vu N Ngo; Jason Glover; Bill H Chang; Arla Yost; Wenxue Ma; Angela G Fleischman; Wenjun Zhou; Yandan Yang; Maria Kleppe; Yebin Ahn; Jessica Tatarek; Michelle A Kelliher; Donna S Neuberg; Ross L Levine; Richard Moriggl; Mathias Müller; Nathanael S Gray; Catriona H M Jamieson; Andrew P Weng; Louis M Staudt; Brian J Druker; A Thomas Look
Journal:  Cancer Discov       Date:  2013-03-07       Impact factor: 39.397

Review 9.  Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders.

Authors:  Geoffrey Shouse; Liana Nikolaenko
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

Review 10.  The molecular regulation of Janus kinase (JAK) activation.

Authors:  Jeffrey J Babon; Isabelle S Lucet; James M Murphy; Nicos A Nicola; Leila N Varghese
Journal:  Biochem J       Date:  2014-08-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.